Ranbaxy narrows Q1 net loss to Rs 186 crore
31 July 2014 3:12 AM IST
The company had posted a net loss of Rs 524.24 crore for the corresponding period of the previous fiscal, Ranbaxy Laboratories said in a statement.
Consolidated net sales of the company stood at Rs 2,372.24 crore for the quarter under consideration as against Rs 2,583.94 crore for the same period year ago.
Branded and OTC category accounted for 58 per cent of total sales during the quarter at Rs 1,370 crore. Generics and others category recorded Rs 1,000 crore of sales for the quarter, it added.
Commenting on the results, Ranbaxy CEO & Managing Director Arun Sawhney said: ‘We continue to work towards growing our base business with focus on emerging markets, while at the same time, restoring the business on growth trajectory in our traditional markets such as USA and Europe.’
In the US, the company posted sales of Rs 700 crore for the quarter primarily driven by AbsoricaTM with a market share of 20 per cent, it added.
The India business of the company recorded 12 per cent growth as against the Indian Pharma Market (IPM) growth of 10 per cent.
Consolidated net sales of the company stood at Rs 2,372.24 crore for the quarter under consideration as against Rs 2,583.94 crore for the same period year ago.
Branded and OTC category accounted for 58 per cent of total sales during the quarter at Rs 1,370 crore. Generics and others category recorded Rs 1,000 crore of sales for the quarter, it added.
Commenting on the results, Ranbaxy CEO & Managing Director Arun Sawhney said: ‘We continue to work towards growing our base business with focus on emerging markets, while at the same time, restoring the business on growth trajectory in our traditional markets such as USA and Europe.’
In the US, the company posted sales of Rs 700 crore for the quarter primarily driven by AbsoricaTM with a market share of 20 per cent, it added.
The India business of the company recorded 12 per cent growth as against the Indian Pharma Market (IPM) growth of 10 per cent.
Next Story
